Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
66 participants
INTERVENTIONAL
2025-03-08
2025-05-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cutaneous Acceptability, Comedogenic Potential and Efficacy of Two Cosmetic Products Used in Synergy
NCT05490537
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
NCT02998671
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris
NCT06403501
Effect of New Topical Preparation for Treatment of Acne Vulgaris
NCT05899699
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
NCT00599521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group Emulsion
Standard Cleanser, Investigational emulsion, Standard moisturizer, Standard Sunscreen
Products Application and Usage Instruction:
Wash out: T-2W \~ T0
Frequency:
AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer Caution: All the products should be applied to full face. No any other skincare or facial make up products are used except provide products.
b. Mode of application : 4-week Treatment T0 \~ T4W
Frequency:
AM: Standard cleanser + test emulsion (FLA#2039180 68) + standard sunscreen PM: Standard cleanser + test emulsion (FLA#2039180 68) Caution: All the products should be applied to full face. No other skincare or facial make up products are used except provide products.
c. Mode of application : 2-week relapse T4W \~ T6W AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer
Usage Instruction: Test emulsion (FLA#2039180 68): Self-application 0.6 ml for full face by hand every day (2x/day).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard Cleanser, Investigational emulsion, Standard moisturizer, Standard Sunscreen
Products Application and Usage Instruction:
Wash out: T-2W \~ T0
Frequency:
AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer Caution: All the products should be applied to full face. No any other skincare or facial make up products are used except provide products.
b. Mode of application : 4-week Treatment T0 \~ T4W
Frequency:
AM: Standard cleanser + test emulsion (FLA#2039180 68) + standard sunscreen PM: Standard cleanser + test emulsion (FLA#2039180 68) Caution: All the products should be applied to full face. No other skincare or facial make up products are used except provide products.
c. Mode of application : 2-week relapse T4W \~ T6W AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer
Usage Instruction: Test emulsion (FLA#2039180 68): Self-application 0.6 ml for full face by hand every day (2x/day).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Acne prone skin with combination to oil and oil skin type.
3. At least 50% self-declared sensitive skin.
4. Presenting with mild to moderate IGA (Acne Severity 0-4 scale, 2-3 score). 1) At least 5 inflammatory acne lesions (papules, pustules) on the global face. 2) At least 10 non-inflammatory acne lesions (blackhead, whitehead) on the global face.
5. Presenting with Cheek Sebaceous Pores (Skin aging ATLAS Vol.2 Asian Type) ≥ 3 score (0-5 scale)
6. At least 1 active inflammatory lesion can be tracked.
7. Subjects with acne red mark (PIE)
8. Presenting with skin lack of smoothness, radiance, brightness, softness evaluated by dermatologist and have skin redness concerns.
1\) Skin smoothness (0-9 scale, 3≤ grade≤ 6) 2) Skin radiance (0-9 scale, 3≤ grade≤ 6) 3) Skin brightness (0-9 scale, 3≤ grade≤ 6) 4) Skin softness (0-9 scale, 3≤ grade≤ 6) 5) Skin redness (0-9 scale, 3≤ grade≤ 6) 9.No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
10.In general good health at the time of the study. 11.Willing and able to participate as evidenced by signing of informed consent and photo release form.
12.Must be willing to comply with all study protocol requirements
Exclusion Criteria
2. With facial hair that may interfere with the assessment or image captured of the test area (applicable only to males);
3. Unable to participate in the trial according to the study schedule or other situations that are unsuitable for participation (e.g. Subject deprived of rights by a court or administrative order. Major subject to a guardianship order. Subject residing in a health or social care establishment. Patient in an emergency setting.)
4. Subject with a skin disease in the test areas (particularly e.g, acne, rosacea, eczema).
5. Subjects with history of atopy, allergic reactions, irritation or intense discomfort feelings to topical-use products, medication, cosmetic or personal care products or ingredients.
6. Subject presenting a stable or progressive serious disease (per investigator's assessment).
7. Immuno-compromised subject.
8. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
9. Subjects regularly practicing aquatic or nautical sports.
10. Subjects regularly attending a sauna.
11. Subject with cardiovascular or circulatory history.
12. Subject with a history of skin cancer or malignant melanoma.
13. Anti-aging medical beauty project or anti-aging cosmetics clinical research in the last 6 months before study.
14. Participants who took oral isotretinoin capsules within the 6 months prior to the testing period.
15. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants in the last 6 months before study.
16. Participants who are currently or have participated in other clinical trials within the past month.
20 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ChinaNorm
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ping Xu, Master
Role: PRINCIPAL_INVESTIGATOR
Shanghai China-norm Quality Technical Service Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai China-norm Quality Technical Service Co., Ltd.
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C25005028
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.